Welcome to our dedicated page for Clene SEC filings (Ticker: CLNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clene Inc. (CLNN) SEC filings page provides access to the company’s official regulatory disclosures as a Nasdaq-listed, late clinical-stage biopharmaceutical issuer. These documents offer detailed insight into Clene’s development of CNM-Au8, its financial position, and the financing structures that support its ALS, MS, and Parkinson’s disease programs.
Investors can review current reports on Form 8-K that Clene files to describe material events. Recent 8-K filings have covered quarterly financial results and operating highlights, equity distribution agreements for at-the-market common stock offerings, prospectus supplements for additional share issuances, amendments to senior secured convertible promissory notes, and new note purchase agreements. Other 8-Ks reference press releases and scientific presentations, such as new clinical data from the REPAIR-MS and REPAIR-PD studies and regulatory updates following FDA Type C and Type B meetings.
Alongside 8-Ks, Clene’s broader SEC reporting (including Forms 10-K and 10-Q, when accessed through EDGAR) details research and development expenses, general and administrative costs, limited product and royalty revenue, and the impact of warrant and derivative liabilities. Filings also describe the terms of convertible notes, including maturity dates, interest capitalization, conversion prices into common stock, and change-of-control provisions, which are important for understanding potential dilution and capital structure.
On Stock Titan, CLNN filings are updated in near real time as they appear on EDGAR. AI-powered summaries highlight key elements of each filing, such as new financing terms, regulatory milestones, or changes in clinical development plans, helping readers quickly interpret complex legal and financial language. Users can also focus on items related to capital raises, note amendments, and other direct financial obligations that shape Clene’s runway for advancing CNM-Au8 through clinical trials and potential regulatory review.
Clene Inc. insider associated entity sells shares in two open-market transactions. An entity linked to ten percent owner Ugwumba Chidozie, identified as SymBiosis II, LLC, sold 4,318 shares of Clene common stock at $6.12 per share on April 20, 2026, followed by 61,345 shares at $6.14 per share on April 21, 2026. After the April 21 sale, the filing reports 297,066 Clene shares indirectly held by this entity.
Clene Inc. ten percent owner Ugwumba Chidozie, through SymBiosis II, LLC, reported open-market sales of Clene common stock over three days. SymBiosis II, LLC sold 6,374 shares at $6.48 on April 15, 7,748 shares at $6.40 on April 16, and 25,040 shares at $6.43 on April 17, leaving 362,729 shares of indirect ownership after the latest transaction.
CLNN filed a Form 144 notice reporting proposed sales of Common Stock, listing an entry of 401,891 shares under “Securities To Be Sold” (dated 09/30/2024) and multiple completed open-market sales by Symbiosis II LLC with trade dates and per-trade share counts and proceeds in 2026. The filing lists open-market purchase / resale activity and indicates cash transactions.
Clene Inc. is asking stockholders to vote at its 2026 Annual Meeting on May 21, 2026, in Salt Lake City. Holders of common stock at the March 25, 2026 record date can vote online, by phone, mail, or in person, with one vote per share.
Stockholders will elect three Class III directors to terms ending in 2029, ratify Deloitte as independent auditor for 2026, and cast an advisory vote on executive pay. A key item seeks to amend the Amended 2020 Stock Plan to add 1,000,000 shares, raising the share reserve from 3,220,000 to 4,220,000.
As of March 25, 2026, Clene had 11,778,307 common shares outstanding, 3,006,484 options outstanding under the plan, and 197,177 shares remaining available for grants. The company discloses a three-year average equity burn rate of 9.99% and estimates fully‑diluted overhang of 22.0%, which would rise to 26.8% if the amendment is approved.
Clene Inc. insider filing shows an indirect share sale by a large holder. On April 2, 2026, SymBiosis II, LLC, an entity associated with ten percent owner Ugwumba Chidozie, completed an open-market sale of 24,925 shares of Clene common stock at $4.81 per share. Following this transaction, the entity continued to hold 401,891 shares of common stock indirectly, indicating the sale represented only a portion of its overall position.
Clene Inc. ten percent owner associated entity sells shares. An entity linked to Ugwumba Chidozie, SymBiosis II, LLC, completed an open-market sale of 4,278 shares of Clene Inc. common stock at $4.97 per share. After this transaction, the entity still holds 426,816 shares indirectly.
CLNN reports multiple proposed and executed sales of Common Stock by Symbiosis II LLC as disclosed on Form 144. The filing lists numerous open-market dispositions on dated entries, including 31,297 shares on 03/31/2026 for $152,316.52 and 32,705 shares on 01/12/2026 for $179,867.17. Transactions are shown across January–March 2026 with individual trade sizes and cash amounts reported per line item.
Clene Inc. ten-percent owner Ugwumba Chidozie, through Symbiosis II, LLC, reported open-market sales of Clene common stock. The LLC sold 67,991 shares at $4.88, 15,536 shares at $5.10, and 17,470 shares at $4.75 per share. Following these transactions, Symbiosis II, LLC continued to hold 431,094 shares of Clene common stock indirectly attributed to Chidozie.
Clene Inc. disclosed that an entity associated with ten percent owner Ugwumba Chidozie, identified as SymBiosis II, LLC, sold a total of 17,909 shares of Clene common stock in three open-market transactions at prices between $5.40 and $5.78 per share. After these indirect sales, SymBiosis II, LLC continued to hold 532,091 Clene shares.